Sol-Gel Technologies Ltd. SLGL
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Sol-Gel Technologies Ltd. (SLGL) is a healthcare company listed in the US with a market value of about $180M. In fiscal year 2025 it had revenue of $19M and net income of -$6M, a net margin of -31.6%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 656.2, 5-year revenue growth of 17% a year, a 5-year average ROIC of -28%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Sol-Gel Technologies
Sol-Gel Technologies is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $174000 in 2017 to $19M in 2025, growth of about 80.2% a year. It was profitable in 1 of the last 10 years in our data. It spends 118% of revenue on research and development.
Score: 2.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19M | $12M | $2M | $4M | $31M | $9M | $23M | $129000 | $174000 | — |
| Net income | -$6M | -$11M | -$27M | -$15M | $3M | -$29M | -$25M | -$32M | -$32M | -$21M |
| Free cash flow | $275000 | -$14M | -$18M | -$10M | -$8M | -$26M | -$23M | -$25M | -$26M | -$19M |
| EPS (diluted) | $-1.87 | $-3.23 | $-8.32 | $-4.56 | $0.98 | $-8.95 | $-7.52 | $-9.84 | $-9.64 | $-6.34 |
| Net margin | -31.6% | -91.7% | -1752.8% | -384.3% | 10.3% | -333.9% | -107.4% | -24963.6% | -18142.5% | — |
| ROIC | -25.0% | -31.5% | -57.5% | -29.8% | 5.2% | -58.0% | -38.1% | -41.4% | -197.7% | -273.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $155.50, 182% above the current price; targets range from $110.00 to $201.00; the consensus rating is “Strong buy”; expected EPS is $-11.80 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Sol-Gel Technologies stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Sol-Gel Technologies pay a dividend?
Not currently.
Is Sol-Gel Technologies a good stock to buy?
We do not give buy or sell advice. Sol-Gel Technologies scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.